Vizora日本語

Pharma Foods InternationalPharma Foods International Co., Ltd.2929東証プライム食料品FY ending Jul 2025, consolidated, J-GAAP

Pharma Foods International FY ending Jul 2022 results

About 43% of Pharma Foods International's sales come from BtoC, with Bio Direct Value and BtoB making up much of the rest.

Out of every ¥100 of sales, about ¥2 is left as operating profit.

Revenue changed +28.7% from the prior year, operating profit -81.0%.

Revenue and profit pattern

Revenue up, profit downRevenue grew faster

Revenue +28.7% · profit -81.0%, calculated from disclosed figures.

Operating leverage: -2.82× (profit growth ÷ revenue growth)

What changed from last year

FY ending Jul 2021 → FY ending Jul 2022

Revenue
+28.7%¥46.8B → ¥60.2B
Gross profit
+21.1%¥39.7B → ¥48.1B
Operating income
-81.0%¥5.67B → ¥1.08B
Net income attributable to owners
-109.7%¥3.84B → -¥374M
Operating cash flow
-202.1%¥5.94B → -¥6.07B
Free cash flow
-213.4%¥5.76B → -¥6.54B

Where the money goes

FY ending Jul 2021 → FY ending Jul 2022

※ Segment revenues include inter-segment sales and are scaled to consolidated revenue

Where ¥100 of sales goes

For every ¥100 Pharma Foods International sells, how much goes where, and how much is kept.

FY ending Jul 2022
Cost of sales
¥20
SG&A
¥78
Operating profit
¥2
Net loss
¥1

Annual margin trends

Gross margin79.9%
FY ending Jul 2019: 81.0%81.0%FY ending Jul 2020: 79.3%79.3%FY ending Jul 2021: 85.0%85.0%FY ending Jul 2022: 79.9%79.9%FY19FY20FY21FY22
Operating margin1.8%
FY ending Jul 2019: 5.5%5.5%FY ending Jul 2020: 4.8%4.8%FY ending Jul 2021: 12.1%12.1%FY ending Jul 2022: 1.8%1.8%FY19FY20FY21FY22
Net margin-0.6%
FY ending Jul 2019: 4.7%4.7%FY ending Jul 2020: 4.5%4.5%FY ending Jul 2021: 8.2%8.2%FY ending Jul 2022: -0.6%-0.6%FY19FY20FY21FY22

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Jul 2022

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第28期(2024/08/01－2025/07/31)

    ID S100WW382025-10-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第27期(2023/08/01－2024/07/31)

    ID S100UKTG2024-10-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第26期(2022/08/01－2023/07/31)

    ID S100S2IX2023-10-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第25期(令和3年8月1日－令和4年7月31日)

    ID S100PDNZ2022-10-20Open

  • EDINET (FSA Japan)

    有価証券報告書－第24期(令和2年8月1日－令和3年7月31日)

    ID S100MMP32021-10-20Open

  • EDINET (FSA Japan)

    有価証券報告書－第23期(令和1年8月1日－令和2年7月31日)

    ID S100JY6D2020-10-20Open

Extracted from XBRL: 55 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image